Pinned Tweet
Replying to @silvertrade
$ZIM is a safe harbour with a great captain behind the thesis.
44 days left until year-end. You’re getting the entire shipping business for free + fat dividends.
@ZeeContrarian1
5
201
Babank retweeted
IF YOU DONT BUY BLOOD, WHEN DO YOU BUY?!?!?
Babank retweeted
$SNAP Earnings: Back To The Free Perpetual Option Price
Market Cap: ~$9B | Earnings Reaction: -13%
$SNAP is back to roughly $5.20, the same price at which I initially recommended it, further reinforcing my original thesis: this is essentially a free perpetual option on Evan Spiegel finally making the right decisions.
Yesterday’s earnings showed revenue growth of 14%, adjusted EBITDA up 110%, and improving profitability and cash flow. On the negative side, advertising growth remains weak at 4%, stock-based compensation is still too high, and Spiegel has yet to make the strategic changes I want to see.
With 977 million monthly active users, $SNAP trades at just $9 per monthly user. Even comparing daily active users, the valuation gap is enormous:
$SNAP: ~$18 per daily user
$RDDT: ~$151 per daily user
$META: ~$442 per daily user
If $SNAP were trading at a $30 billion valuation, I would avoid it all together. But at just $9 billion, with improving profitability and cash generation, it’s hard for me to see the stock going substantially lower from here.
Unlike many growth companies, $SNAP doesn’t need to invent a new business or find hundreds of millions of new users. It already has nearly a billion users. It simply needs to monetize them better, something $META has beautifully demonstrated can be achieved through AI.
Evan Spiegel also needs to have the same realization Mark Zuckerberg eventually had about the metaverse: spending billions on a project doesn’t necessarily mean it will become a profitable business. The difference is that Specs actually have compelling real-world applications, but $SNAP needs a partner to share the costs, risks and development.
I believe Spiegel knows this. The day he announces a serious partner that de-risks Specs, I wouldn’t be surprised to see $SNAP jump 20% or more in a single day. And that’s just one of several possible catalysts, alongside better advertising monetization, reduced stock-based compensation and improved capital allocation.
None of these changes seems like a particularly tall order. Until then, perhaps $5-$6 is exactly where the stock deserves to trade. We’re essentially waiting for something to change, and if it does, the upside could be substantial. If it doesn’t, I believe the low valuation and enormous user base provide a meaningful margin of safety.
I recommended taking some profits when the stock rose from $5 towards $7 without any news to justify the move. Now that we’re back near $5, I believe the entry point is attractive again.
My Action: I’m Buying the Dip.
We’re starting to see measurable improvements in $SNAP ’s financial performance, and I believe the market’s 12% punishment following earnings was too harsh.
Of course, nothing is guaranteed. Spiegel could continue making the same mistakes, and the stock could remain depressed for years, but it’s hard to justify valuing a company with more than 900 million monthly users at less than $9 billion.
That’s what I mean by a free perpetual option. Heads, I win big. Tails, I barely lose.
Babank retweeted
$STAA: The Turnaround Continues
Market Cap: ~$1.5B | Yesterday Earnings Reaction: +9% | Last Month: +30%
For those unfamiliar with $STAA, STAAR Surgical is the global leader in implantable lenses for vision correction, an alternative to LASIK that doesn’t require removing corneal tissue. The company has a relatively strong moat, built on proprietary Collamer technology, regulatory approvals, decades of clinical data and relationships with eye surgeons. When it comes to your eyes, you’re not going to put something inside them that hasn’t been tested in other people’s eyes for at least 5 to 10 years. Competitors have faced safety problems with implantable lenses in the past that where considered “the next big thing”, making STAAR’s long clinical track record a substantial competitive advantage.
I initially recommended $STAA at $17.50, following the proposed $30.75 acquisition by Alcon, which was opposed by Broadwood Partners, a hedge fund owning approximately 30% of the company, on the grounds that the offer was too opportunistic.
Yesterday’s earnings further reinforced my investment thesis. Revenue reached $83.4M, representing 21% underlying growth, with China up 31% and Europe up 31%. Adjusted EBITDA improved to $14.4M, net income reached $5.6M, and cash increased to $206M with zero debt. For the first nine months of 2026, revenue reached $270.5M and adjusted EBITDA $58.8M. Management also authorized a $50M share buyback.
Gross margins remain under pressure at 70.9%, but management expects improvement beginning in Q4 and continuing into 2027.
The important story is how much the business has changed since the acquisition offer. If you’ve followed my tweets, you know that the underlying business has improved substantially. I would argue that the company’s situation today is many times better than when the $30.75 offer was made and subsequently rejected.
Just before the latest earnings, Steve Cohen’s Point72 acquired approximately 5% of the company at around $29 per share. Despite the stock’s recent 45% rally, we’re only now back to roughly the price at which Point72 established its position.
With a strong balance sheet, recovering profitability and growing demand for its products, I believe there’s considerably more upside. It’s not hard for me to see $STAA reaching $50 per share with patience.
Following its 45% rise, $STAA is now my second-largest position.
For my full research report and original investment thesis, see the tweet below.
𝗦𝗧𝗔𝗔𝗥 𝗦𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗹𝗼𝗼𝗸𝘀 𝗹𝗶𝗸𝗲 𝗮 𝗰𝗹𝗮𝘀𝘀𝗶𝗰 𝗰𝗼𝗻𝘁𝗿𝗮𝗿𝗶𝗮𝗻 𝘀𝗲𝘁𝘂𝗽, 𝗯𝘂𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝗰𝗲 𝗶𝘀 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗱
$17.40 stock price | ~$187M cash | Enterprise value ~$700–725M
STAAR Surgical ( $STAA ) today sits in an uncomfortable place in the market, which is often where the more interesting opportunities begin.
The company is small, with a market capitalization of roughly $850 million and an enterprise value closer to $700 million once you account for its ~$187 million in cash and no debt. It operates in the shadow of much larger players like Alcon ( $ALC ), Johnson & Johnson ( $JNJ ), and Bausch + Lomb ( $BLCO ), yet it occupies a part of the market those players do not fully control.
STAAR’s business is simple to describe and difficult to replicate. It implants a lens inside the eye to correct vision, rather than reshaping the cornea like LASIK. The procedure is particularly effective for myopia, or nearsightedness, a condition where distant objects appear blurry because the eye focuses images incorrectly. Myopia is rising globally, especially in Asia, which is one reason the category has grown so quickly.
The company’s approach has clear advantages in certain cases. It is reversible, it preserves the cornea, and it often delivers better outcomes for patients with moderate to severe myopia who are not ideal candidates for LASIK. It also requires surgeon training, regulatory approvals, and years of accumulated experience, which together create a real, if not absolute, moat.
For years, the story worked. Growth was strong, margins were high, and China became the engine. Then the company ran into a classic problem, not of demand disappearing but of inventory building up in the channel. Management stopped shipments to reset the system, and reported sales collapsed, especially in China. The market treated that as a broken story rather than a reset.
The stock followed, falling to around $17.40.
At the same time, strategic interest emerged. About a year and a half ago, there were credible discussions around a sale above $50 per share. More recently, Alcon ( $ALC ) made a firm cash offer that was ultimately raised to about $30.75 per share.
That deal failed.
Broadwood Partners, the largest shareholder and a holder for more than 15 years, blocked it. They argued the process was poorly timed and did not reflect the true value of the business. They were also critical of how the go-shop was conducted, describing it as rushed and restrictive, limiting the ability of other bidders to properly engage and complete due diligence.
Broadwood’s position is not that the company should never be sold. It is that it should not be sold here. They have indicated they would be open to a transaction, but only after the business stabilizes and reflects normalized performance. They had no interest in selling at around $30 in the middle of a downturn.
From their perspective, that would have meant selling a unique asset at a cyclical low. They continue to believe the company is worth significantly more.
That leaves the stock in a familiar contrarian position. A differentiated business, a real moat, a strong balance sheet, and a product still being adopted globally, but a narrative dominated by one disrupted geography.
The question is no longer what STAAR does.
The question is whether China was a temporary reset or a permanent peak.
Broadwood is clearly betting the house on the answer. They knew rejecting a $30.75 offer would likely send the stock lower, and it did, yet they still blocked the deal. The position represents roughly 20% of their fund, implying unusually high conviction.
Either way, this is not a short-term situation. The setup may be contrarian, but the resolution will take time, so no rush to buy.
Babank retweeted
$TE - going to add shares here at $2.95.
Got the idea from a friend.
Babank retweeted
$WGS there we go:
Babank retweeted
when the market hands us heavy losses, up to us to take the hint and focus on the areas where we are having greater success
Babank retweeted
$WGS - Reloading the play with Zee. Man just sized up to 8% of the port like it's nothing. Pure conviction 🚀
Babank retweeted
Markets don’t peak because of valuations. They never have, and they never will. Take the dot-com bubble: it burst when liquidity dried up, profitless companies ran out of cash, and sentiment collapsed. Valuations were just the excuse after the fact.
Babank retweeted
What I love most about $BTDR is that almost nobody is talking about it on X. That is already a very good sign.
Two of the best investors I know, whom I have spoken with over the past couple of months, are big fans of the company. These are serious long-term investors, and I have watched many of their ideas go up several times.
Stanley Druckenmiller also disclosed around 4.1 million $BTDR shares, worth approximately $65 million, when the stock was trading at higher prices than it is today.
$BTDR is his largest disclosed position in the Bitcoin-mining and data-center sector. It is around 16 times larger than his position in the much more popular $IREN. He disclosed no positions in $CRWV or $NBIS.
Until now, $BTDR has been followed mostly by the really smart money, while the average Joe on X is still busy somewhere else.
That is normally where I like to be.
Babank retweeted
$SNAP I like the risk/reward here around $6. Pretty cool tech. Starter long and will add on strength.
Snap Co-founder and CEO Evan Spiegel will share the first in-depth look at SPECS, demonstrating how they bring AI assistance, work tools, entertainment, and shared experiences into the world around us. nitter.gq/i/broadcasts/1rxmqpgeW…



























